These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 22570338

  • 1. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
    Wang S, Li X, Qu L, Wang R, Chen Y, Li Q, He X, Zhang X, Wang H, Wu J, Xu Y, Chen J.
    Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
    [Abstract] [Full Text] [Related]

  • 2. Tacrolimus as a steroid-sparing agent for adults with steroid-dependent minimal change nephrotic syndrome.
    Li X, Li H, Chen J, He Q, Lv R, Lin W, Li Q, He X, Qu L, Suya W.
    Nephrol Dial Transplant; 2008 Jun; 23(6):1919-25. PubMed ID: 17911091
    [Abstract] [Full Text] [Related]

  • 3. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
    Li X, Lv R, He Q, Li H, Du X, Lin W, Li Q, He X, Wang S, Chen J.
    J Nephrol; 2008 Jun; 21(4):584-91. PubMed ID: 18651550
    [Abstract] [Full Text] [Related]

  • 4. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
    Li H, Shi X, Shen H, Li X, Wang H, Li H, Xu G, Chen J.
    Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
    [Abstract] [Full Text] [Related]

  • 5. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC, Ying KY, Tang S, Leung CY, Lee KW, Ng WL, Wong RW, Lau CS.
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [Abstract] [Full Text] [Related]

  • 6. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R.
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [Abstract] [Full Text] [Related]

  • 7. Long-term data on tacrolimus treatment in lupus nephritis.
    Yap DY, Ma MK, Mok MM, Kwan LP, Chan GC, Chan TM.
    Rheumatology (Oxford); 2014 Dec; 53(12):2232-7. PubMed ID: 24996908
    [Abstract] [Full Text] [Related]

  • 8. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
    Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC.
    Am J Kidney Dis; 2001 Aug; 38(2):256-64. PubMed ID: 11479150
    [Abstract] [Full Text] [Related]

  • 9. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.
    Tanaka H, Oki E, Tsuruga K, Yashiro T, Hanada I, Ito E.
    Clin Nephrol; 2009 Dec; 72(6):430-6. PubMed ID: 19954719
    [Abstract] [Full Text] [Related]

  • 10. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
    Fischer-Betz R, Chehab G, Sander O, Vordenbäumen S, Voiculescu A, Brinks R, Schneider M.
    J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
    [Abstract] [Full Text] [Related]

  • 11. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids.
    He L, Peng Y, Liu H, Liu Y, Yuan S, Liu F, Yang D, Liu H, Chen X, Shao J, Fu M.
    J Nephrol; 2013 Nov; 26(3):564-71. PubMed ID: 22956434
    [Abstract] [Full Text] [Related]

  • 12. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
    Szeto CC, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Gang W, Li PK.
    Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192
    [Abstract] [Full Text] [Related]

  • 13. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N, Ingsathit A, Rattanasiri S, Ngamjanyaporn P, Kasitanont N, Chawanasuntorapoj R, Pichaiwong W, Anutrakulchai S, Sangthawan P, Ophascharoensuk V, Avihingsanon Y, Sumethkul V.
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [Abstract] [Full Text] [Related]

  • 14. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
    Grootscholten C, Snoek FJ, Bijl M, van Houwelingen HC, Derksen RH, Berden JH, Dutch Working Party of SLE.
    J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
    [Abstract] [Full Text] [Related]

  • 15. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
    Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL.
    Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
    [Abstract] [Full Text] [Related]

  • 16. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR.
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [Abstract] [Full Text] [Related]

  • 17. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice.
    Tanaka H, Watanabe S, Aizawa-Yashiro T, Oki E, Kumagai N, Tsuruga K, Ito E.
    Nephron Clin Pract; 2012 Sep; 121(3-4):c165-73. PubMed ID: 23327881
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial.
    Chen W, Liu Q, Chen W, Tang X, Fu P, Liu F, Liao Y, Yang Z, Zhang J, Chen J, Lou T, Fu J, Kong Y, Liu Z, Li Z, Yu X.
    Lupus; 2012 Aug; 21(9):944-52. PubMed ID: 22438027
    [Abstract] [Full Text] [Related]

  • 19. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.
    Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, Gu Y, Shi W, Hu W, Liu Z, Bao H, Zeng C, Zhou M.
    Ann Intern Med; 2015 Jan 06; 162(1):18-26. PubMed ID: 25383558
    [Abstract] [Full Text] [Related]

  • 20. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A, Hada R, Agrawal RK, Bhattarai GR, Baral A.
    BMC Nephrol; 2018 Jul 11; 19(1):175. PubMed ID: 29996800
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.